ScoreHaematology
Smouldering myeloma progression risk (IMWG 2/20/20 and risk score)
Estimates the 2-year risk that smouldering multiple myeloma progresses to active myeloma.
Updated 31 October 2026
When to use it
Patients with smouldering myeloma (no myeloma-defining events) at diagnosis, to plan follow-up or consider early-treatment trials.
What it needs
- Free light chain ratio (involved/uninvolved)
- Serum M-protein
- Bone marrow plasma cells (higher of biopsy or aspirate)
- FISH showing t(4;14), t(14;16), 1q gain or del(13q)/monosomy 13
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 4 | 0–4: low risk (≈ 4 % at 2 years) |
| 5–8 | 5–8: low-intermediate risk (≈ 26 % at 2 years) |
| 9–12 | 9–12: intermediate risk (≈ 51 % at 2 years) |
| ≥ 13 | > 12: high risk (≈ 73 % at 2 years) |
In the app it also calculates: 2-year progression risk predicted by the score, 2/20/20 factors present, 2/20/20 factors + high-risk cytogenetics.
Practical tip
The 2/20/20 model counts three factors: M-protein > 2 g/dL, involved/uninvolved free light chain ratio > 20 and marrow plasma cells > 20 %.
3 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
